- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Salix Pharmaceuticals Ltd
Add to PortfolioSLXP:US
50.8700 USD 0.3700 0.73%As of 20:10:00 ET on 05/25/2012.
Snapshot for Salix Pharmaceuticals Ltd (SLXP)
| Open: | 50.1400 | Day's Range: | 50.1400 - 51.3799 | Volume: | 404,959 | Bid: | 50.8200 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 50.5000 | 52wk Range: | 25.6400 - 53.9900 | 1-Yr Rtn: | +30.97% | Ask: | 50.8700 |
Key Statistics for SLXP
| Current P/E Ratio (ttm) | 25.5628 |
|---|---|
| Estimated P/E (12/2012) | 19.1817 |
| Earnings Per Share (USD) (ttm) | 1.9900 |
| Est. EPS (USD) (12/2012) | 2.6520 |
| Est. PEG Ratio | 0.8840 |
| Market Cap (M USD) | 2,953.48 |
| Shares Outstanding (M) | 58.06 |
| Enterprise Value (M USD) (ttm) | 3,138.84 |
| Enterprise Value/EBITDA (ttm) | 15.75 |
| Price/Book (mrq) | 6.2065 |
| Price/Sale (ttm) | 4.9524 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/08/2012 |
More SLXP Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for SLXP
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for SLXP
Salix Pharmaceuticals, Ltd. develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. The Company markets its products to gastroenterologists in the U.S. through its own specialty sales force.
| Thomas W D'AlonzoChairman | Carolyn J LoganPresident/CEO |
| Adam C DerbyshireExec VP:Finance & Admin/CFO | William P ForbesExec VP:Research & Dev |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page